Abortion Drugs & Practices

60 articles

Abortion Drugs & Practices

Louisiana Attorney General Liz Murrill announced federal lawsuits against New York, California, and Massachusetts for enabling mail-order abortions by refusing to extradite abortionists charged with sending abortion pills into Louisiana, where elective abortion is banned. The state argues that these 'shield' laws violate Louisiana's sovereignty and criminal laws, citing cases where mailed abortion drugs resulted in the deaths of babies and harm to women, and is also challenging the FDA's 2023 policy allowing telehealth prescribing and mail delivery of abortion pills in federal court.

Read →
Steven Ertelt|LifeNews.com|New
Abortion Drugs & Practices

Louisiana Attorney General Liz Murrill, along with Alabama and Arkansas attorneys general, filed two lawsuits targeting abortion pill providers and challenging blue-state shield laws that block prosecution of these providers, with a Supreme Court case against New York, California, and Massachusetts and a separate lawsuit in Louisiana against over 30 individuals and organizations. The complaints allege illegal distribution of abortion pills into states banning abortions, highlight refusal by governors of New York and California to extradite indicted doctors, and describe investigations revealing unsupervised online prescriptions and cases of coerced abortion pill use, while also seeking more federal action and challenging FDA rules on mifepristone dispensing.

Read →
Fox News|New
Abortion Drugs & Practices

Louisiana, Mississippi, and Arkansas have filed a lawsuit at the U.S. Supreme Court challenging abortion 'shield' laws in New York, California, and Massachusetts that protect providers who mail abortion pills into pro-life states. The states argue these laws violate federal statutes and undermine their ability to enforce pro-life protections.

Read →
The Washington Times|New
Abortion Drugs & Practices

The FDA has delayed safety reviews of the abortion drug mifepristone for 26 years and recently argued in court that pro-life states like Louisiana lack standing to sue over its chemical abortion regulations. Louisiana is challenging the FDA's 2021 decision to allow mifepristone to be mailed, which weakened safety protocols and has led to illegal abortions in pro-life states, but the FDA and the drug manufacturer argue that Louisiana must first petition the FDA and that such petitions would not necessarily fail, despite past delays and lack of response from the agency.

Read →
Abortion Drugs & Practices

Cases where women were coerced or forced to take abortion pills by their partners, including incidents in Wisconsin and Louisiana, highlighting the ease of obtaining abortion pills online without proper safeguards. It also reports on a federal lawsuit against the FDA and an OB-GYN's test showing that online abortion pill providers do not verify identities or medical conditions, allowing potentially dangerous situations for women to occur.

Read →
Abortion Drugs & Practices

The Fifth Circuit Court of Appeals recently heard oral arguments in State of Louisiana v. FDA, a case challenging the FDA's policy allowing chemical abortion drugs to be mailed without an in-person medical exam, a policy initiated during the Covid-19 pandemic and continued by both the Biden and Trump administrations.

Read →
Michael New Ph.D.|LifeNews.com|
Abortion Drugs & Practices

Alliance Defending Freedom is challenging the FDA's policy that allows abortion drugs like mifepristone to be mailed, arguing it undermines state laws that prohibit abortion and can lead to coercion, as in the case of Rosalie Markezich in Louisiana. Pro-life organizations, including Family Council, have filed legal briefs and are urging the federal government to reverse the FDA's mail-order abortion drug policy, citing health risks and the need for in-person medical oversight.

Read →
Jerry Cox|LifeNews.com|
Abortion Drugs & Practices

Novielli reviews oral arguments in Louisiana's challenge to federal rules permitting mailed abortion pills. She describes the state's claims of legal and financial harm and criticism of the federal government's focus on standing.

Read →
Abortion Drugs & Practices

The U.S. Fifth Circuit Court of Appeals heard arguments in the Louisiana vs FDA case regarding the FDA's 2023 decision to remove the requirement for an in-person doctor visit before receiving an abortion pill, which Louisiana claims has led to unsafe mailing of abortion pills.

Read →

Showing 25 of 60

Loading more…